[Efficacies and clinical roles of new antifungal agents].

Abstract

Micafungin, a new class of the antifungal agent "echinocandin" released in 2002, and voriconazole, a new triazole antifungal agent released in 2005 in Japan have in vitro activities against Aspergillus spp. Results of large-scale clinical trials in Europe and the United States showed voriconazole to have superior efficacy against invasive pulmonary aspergillosis in comparison with conventional amphotericin B, and caspofungin, a member of the echinocandins, was effective as an empirical antifungal therapy in patients with persistent fever and neutropenia. In this way, choices of therapeutic medicine for aspergillosis are increasing more and more, and it is expected that the method of treatment will change greatly in future. On the other hand, we need to establish a new standard therapy for aspergillosis to avoid the clinical disruption caused by the variety of pharmaceutical choice caused. In this report, we describe the role of new antifungal agents for non-fumigatus Aspergillus infections, and the breakthrough in counteracting fungal infection using these new drugs.

• Authors: Issei Tokimatsu, Jun-ichi Kadota
• Journal: Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology (Nihon Ishinkin Gakkai Zasshi) Vol. 47 Issue 3 Pg. 155-9 ( 2006) ISSN: 0916-4804 [Print] Japan
• PMID: 16940948 (Publication Type: Journal Article, Review)

Chemical References

• Antifungal Agents
• Echinocandins
• Lipopeptides
• Lipoproteins
• Peptides, Cyclic
• Pyrimidines
• Triazoles
• Caspofungin
• Voriconazole
• Micafungin

Topics

• Antifungal Agents (therapeutic use)
• Aspergillosis (drug therapy)
• Caspofungin
• Echinocandins
• Humans
• Lipopeptides
• Lipoproteins (therapeutic use)
• Micafungin
• Peptides, Cyclic (therapeutic use)
• Pyrimidines (therapeutic use)
• Triazoles (therapeutic use)
• Voriconazole